Amneal (AMRX) Officer Jason Daly Disposes 22,000 Shares at $9.05

Rhea-AI Filing Summary

Amneal Pharmaceuticals insider sale: Jason B. Daly, EVP and Chief Legal Officer, sold 22,000 shares of Class A common stock at a weighted average price of $9.05 per share on 08/12/2025. After the reported sale, Daly directly holds 10,606 shares. The filing notes the sale was executed in multiple transactions with prices ranging from $9.01 to $9.13 and that full per-trade details will be provided to the company or the SEC on request. The Form 4 was submitted by an attorney-in-fact on behalf of the reporting person.

Positive

• None.

Negative

• Officer disposed of 22,000 Class A shares, reducing direct holdings to 10,606 shares.
• Sale price disclosed as weighted average $9.05, with trades ranging $9.01–$9.13 (per footnote).

Insights

Securities Analyst

TL;DR: Officer sale of 22,000 shares at weighted $9.05 reduces Daly's direct stake to 10,606 shares; routine Form 4 disclosure.

The Form 4 reports a direct sale (transaction code S) of 22,000 Class A shares by Jason B. Daly, an officer (EVP, Chief Legal Officer). The filing specifies a weighted average price of $9.05 and a disclosed per-trade price range of $9.01 to $9.13. After the disposition Daly retains 10,606 shares directly. This is a standard Section 16 disclosure of an insider sale with a commitment to provide per-trade detail upon request.

Corporate Governance Expert

TL;DR: Transaction executed via attorney-in-fact; disclosure includes weighted average price and footnote on price range, consistent with compliance practice.

The filing was signed by an attorney-in-fact, indicating the sale paperwork was completed through a designated representative. The footnote clarifies the reported price is a weighted average from multiple trades between $9.01 and $9.13 and commits to furnish detailed allocations if requested. The disclosure follows Form 4 requirements for officer transactions and documents the change in direct beneficial ownership.

Insider Trade Summary

Net Seller: 22,000 shares

Net Sell 1 txn

Insider Daly Jason B.

Role EVP, Chief Legal Officer

Sold 22,000 shs ($199K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	22,000	$9.05	$199K

Holdings After Transaction: Class A Common Stock — 10,606 shares (Direct)

Footnotes (1)

1. F1. The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.01 to $9.13 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 08/13/2025 - 04:39 PM Learn about SEC filing dates

FAQ

What did AMRX insider Jason Daly do in this Form 4 filing?

He sold 22,000 Class A shares of Amneal Pharmaceuticals, Inc., reported on the Form 4.

At what price were the AMRX shares sold by Jason Daly?

Weighted average price $9.05 per share, with individual trades ranging from $9.01 to $9.13.

How many AMRX shares does Jason Daly own after the transaction?

10,606 shares directly beneficially owned following the reported sale.

When was the transaction reported to have occurred?

Transaction date listed as 08/12/2025 in the Form 4 disclosure.

Who signed the Form 4 on behalf of the reporting person?

Denis Butkovic, Attorney-in-Fact signed the Form 4 for the reporting person.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Daly Jason B.

(Last) (First) (Middle)

C/O AMNEAL PHARMACEUTICALS, INC.

400 CROSSING BOULEVARD

(Street)

BRIDGEWATER NJ 08807

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Amneal Pharmaceuticals, Inc. [ AMRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	08/12/2025		S		22,000	D	$9.05(1)	10,606	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.01 to $9.13 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote.

Remarks:

	/s/ Denis Butkovic, Attorney-in-Fact	08/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.